Atlas of Genetics and Cytogenetics in Oncology and Haematology


Home   Genes   Leukemias   Solid Tumours   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA

LZTS1 (leucine zipper, putative tumor suppressor 1)

Written2012-06Andrea Vecchione, Luca Lavra, Carlo M Croce
Department of Molecular Virology, Immunology, Medical Genetics, Comprehensive Cancer Center, Ohio State University, OH, USA (AV, CMC); Division of Pathology, Medical Oncology, Department of Clinical, Molecular Medicine, Faculty of Medicine, Psychology, University Sapienza, Santo Andrea Hospital, Rome, Italy (AV, LL)

(Note : for Links provided by Atlas : click)

Identity

Alias_namesleucine zipper
Alias_symbol (synonym)FEZ1
Other aliasF37
HGNC (Hugo) LZTS1
LocusID (NCBI) 11178
Atlas_Id 367
Location 8p21.3  [Link to chromosome band 8p21]
Location_base_pair Starts at 20103676 and ends at 20112803 bp from pter ( according to hg19-Feb_2009)  [Mapping LZTS1.png]
Local_order According to the NCBI map viewer, genes flanking LZTS1 from centromere to telomere are:
- CLU (8p21-p12): clusterin
- PTK2B (8p21.1): protein tyrosine kinase 2 beta
- LPL (8p22): lipoprotein lipase
- NAT2 (8p22): N-acetyltransferase 2 (arylamine N-acetyltransferase)
- CTSB (8p22): cathepsin B
- ANGPT2 (8p23.1): angiopoietin 2.
Note The human LZTS1 gene maps on chromosome 8p22 and encodes a leucin zipper protein with a region homologue to cAMP-responsive transcription factor Atf-5, and with different potential phosphorylation sites. It is ubiquitously expressed in normal human tissues and is implicated in cell cycle control by modulating the activity of the Cdk1/cyclin B1 complex. LZTS1 chromosomal locus is frequently deleted in tumors (Ishii et al., 1999) and LZTS1 gene and protein expression is reduced or lost in different human malignancies. The reintroduction of LZTS1 expression into LZTS1 null cancer cell lines suppresses cell growth at the G2/M phase of the cell cycle and inhibits migration and invasion. In conclusion, LZTS1 loss is involved in the neoplastic transformation of different types of tumors indicating that LZTS1 can be considered an important tumor suppressor gene and a potential diagnostic and therapeutic target (Ishii et al., 2001; Vecchione et al., 2002; Vecchione et al., 2007a).

DNA/RNA

Note NC_000008.10: 20103676 - 20112803 bp (Entrez-Gene).
 
  Genomic structure of the human LZTS1 gene.
Description According to Entrez-Gene, LZTS1 gene extends over 9 kb (9128 bases) and consists of 3 exons.
Transcription mRNA size: 5459 bp (NM_021020.2); open reading frame: 1791 bp (NP_066300.1).
LZTS1 mRNA is highly expressed in testis, prostate, spleen, thymus, ovary and brain. It has been detected at lower levels in heart, placenta, small intestine, colon, liver, kidney, skeletal muscle and pancreas. LZTS1 gene is not expressed in primary tumors from breast and prostate and in different cancer cell lines (Ishii et al., 1999).
Pseudogene No LZTS1 pseudogenes have been reported.

Protein

 
  Schematic representation of LZTS1 protein. The leucine residues position of leucine-zipper motifs are indicated by the gray bars.
Description LZTS1 gene encodes a 596-aa protein of 67 kDa. The protein contains two leucine-zipper motifs, multiple potential phosphorylation sites for different kinases (e.g. PKA, CDC2 and PKC) and a domain with 32% identity to the DNA binding domain of the cAMP-responsive transcription factor Atf5. LZTS1 lacks the DNA recognition domain usually found in transcription factors carrying a leucine-zipper motive (Ishii et al., 1999; Ishii et al., 2001; Vecchione et al., 2007b).
Expression LZTS1 is ubiquitously expressed in all normal human tissues. LZTS1 protein expression is lost or reduced in different primary tumors.
Localisation Main sub-cellular localizations: plasma membrane and cytoplasm.
Additional localizations: nucleoli (observed in U2-OS cells) and Golgi apparatus (observed in A-431 cells) (Barbe et al., 2008).
Function Cell cycle regulation. It has been demonstrated that Lzts1-/- mouse embryonic fibroblasts (MEF) have a faster M phase, associated with a lower cyclin B1/Cdk1 activity. During prophase the interaction between LZTS1 and Cdc25C, a phosphatase implicated in regulation of Cdk1 activity, allows the expression of high levels of Cdc25C and enhances its activity, resulting in normal progression from prophase to metaphase. In Lzts1 deficient cells during prophase Cdc25C is rapidly ubiquitinated and degraded, thus determining a lower activity of the cyclin B1/Cdk1 complex. This results in a faster cellular progression through prophase and prometaphase and, frequently, in chromosome missegregation (Vecchione et al., 2007b).
Homology The LZTS1 gene is conserved in the organisms listed below:
- Pan troglodytes (LZTS1) (Gene ID: 464034)
- Macaca mulatta (LZTS1) (Gene ID: 705724)
- Mus musculus (Lzts1) (Gene ID: 211134)
- Rattus norvegicus (Lzts1) (Gene ID: 266711)
- Bos taurus (LZTS1) (Gene ID: 539634)
- Equus caballus (LZTS1) (Gene ID: 100053630)
- Canis lupus familiaris (LZTS1) (Gene ID: 486136)
- Monodelphis domestica (LZTS1) (Gene ID: 100030407)
- Ornithorhynchus anatinus (LZTS1) (Gene ID: 100073437)
- Gallus gallus (LZTS1) (Gene ID: 431331)
- Danio rerio (si:dkey-63d15.13) (Gene ID: 569281).

Mutations

Note Sequence analysis of LZTS1 ORF, performed in different type of cancers revealed the presence of the somatic point mutations listed hereinafter (Vecchione et al., 2001; Knowles et al., 2005):
- S29P: (TCC->CCC) reported in a primary esophageal tumor
- K119E: (AAG->GAG) reported in a primary esophageal tumor
- Q501Stop: (CAG->TAG) reported in PC3 (prostate cancer cell line)
- H17R: (CAC->CGC) reported in a diffuse-type gastric carcinoma
- L113P: (CTA->CCA) reported in a bladder tumor sample
- G374S: (GGC->AGC) reported in A1698 (bladder cancer cell line)
- L475V: (CTG->GTG) reported in SCaBER (bladder cancer cell line).

Internally truncated transcripts described in different cancers (Ishii et al., 1999):
- Frameshift deletion 1546-1542 (exons affected: 1,2,3) reported in esophagus cancer
- In-frame deletion 558-1715 (exons affected: 2,3) reported in esophagus cancer
- In-frame deletion 1366-1641 (exon affected: 3) reported in prostate cancer
- In-frame deletion 1402-1578 (exon affected: 3) reported in esophagus and prostate cancer and in acute lymphoblastic leukemia
- In-frame deletion 1417-1515 (exon affected: 3) reported in melanoma
- In-frame deletion 1516-1584 (exon affected: 3) reported in melanoma.

A detailed DNA sequence analysis of LZTS1 gene performed in germline DNA extracted from a screening panel of sporadic and hereditary prostate cancers revealed the presence of 24 SNP. The four SNP listed below have a statistically significant association with sporadic prostate cancer (Hawkins et al., 2002):
- A allele of WF101-010 (2812G → A)
- C allele of WF101-012 (2883T → C)
- C allele of WF101-031 (3329C → T)
- G allele of WF101-014 (4361C → T).

Implicated in

Note
  
Entity Prostate cancer
Note The DNA sequence analysis of LZTS1 performed on sporadic and hereditary prostate cancer (HPC) samples and unaffected controls revealed the presence of several SNPs associated with prostate cancer (Hawkins et al., 2002). Over-expression of LZTS1 cDNA modulates colony-forming efficiency and proliferation in different prostate cancer cell lines (Cabeza-Arvelaiz et al., 2001).
  
  
Entity Ovarian cancer
Note An immunohistochemical analysis of LZTS1 protein expression performed in ovarian carcinomas tissue samples demonstrated that cytoplasmic staining for FEZ1 protein was absent or drastically reduced in 38% of cases (Califano et al., 2010). In addition, homozygous deletions at LZTS1 locus has been detected in advanced ovarian clear cell carcinomas (Kuo et al., 2010).
  
  
Entity Oral squamous cell carcinoma
Note Reduced LZTS1 gene expression has been reported in 35% of oral squamous cell carcinoma (SSC) samples and in oral SSC-derived cell lines (Ono et al., 2003).
  
  
Entity Uveal melanoma
Note A gene expression profiling performed on 53 primary uveal melanomas by array-based comparative genomic hybridization demonstrated that LZTS1 expression was reduced in rapidly metastasizing and metastatic uveal melanomas but not in slowly metastasizing and non metastasizing uveal melanomas.
Moreover overexpression of LZTS1 in metastasizing uveal melanoma-derived cells inhibited their motility and invasion (Onken et al., 2008).
  
  
Entity Lung carcinoma
Note The immunohistochemical analysis of LZTS1 expression in 103 primary lung cancer specimens demonstrated absence or strong reduction in respectively in more that 42% of cases. A positive correlation between loss of LZTS1 and tumor grading, and between strong LZTS1 expression and mortality rate reduction was also observed (Nonaka et al., 2005). Moreover reduced LZTS1 expression was also detected in several lung cancer derived cell lines (Toyooka et al., 2002).
  
  
Entity Gastric carcinoma
Note The immunohistochemical analysis of LZTS1 expression, performed in 88 gastric cancer specimens demonstrated that it is lost or significantly reduced in more than 44% of cases. In addition, DNA allelotyping analysis at the LZTS1 locus showed LOH and microsatellite instability respectively in 18% and 23,5% of cases (Vecchione et al., 2001).
  
  
Entity Breast carcinoma
Note LZTS1 gene expression was reduced in breast primary tumors and breast cancer cell lines. The immunohistochemical analysis of LZTS1 expression demonstrated that LZTS1 was absent or down-regulated in primary breast carcinomas compared with normal breast. Moreover, reduced LZTS1 expression was significantly correlated with high histologic grade, lymph node metastasis, and poor prognosis. In addition, DNA methylation analysis demonstrated that LZTS1 loss of expression in breast tumors is correlated with gene methylation. Moreover, overexpression of LZTS1 in breast cancer cell lines inhibits cell proliferation, migration and invasion, and induces morphological and molecular changes characteristic of mesenchymal-to-epithelial transition (Chen et al., 2009; Wang et al., 2011).
  
  
Entity Bladder cancer
Note LZTS1 protein expression is reduced in bladder tumor samples and bladder cancer derived cell lines. Reintroduction of LZTS1 expression in TCC derived cell line inhibited cell growth, altered cell cycle progression and suppressed subcutaneous tumor growth in nude mice. Several LZTS1 somatic point mutations have also been reported in bladder cancers tissues and cell lines (Vecchione et al., 2002; Knowles et al., 2005). Moreover, it has been demonstrated by treating heterozygous and nullizygous Lzts1 mice with a classical bladder carcinogen (N-butyl-N-(4-hydroxybutil) nitrosamine, BBN), that the loss of one or both Lzts1 alleles favored development of bladder cancer. These results demonstrated that LZTS1 could represent an important therapeutic target for bladder tumor treatment.
  

Bibliography

Fez1/Lzts1-deficient mice are more susceptible to N-butyl-N-(4-hydroxybutil) nitrosamine (BBN) carcinogenesis.
Baffa R, Fassan M, Sevignani C, Vecchione A, Ishii H, Giarnieri E, Iozzo RV, Gomella LG, Croce CM.
Carcinogenesis. 2008 Apr;29(4):846-8. Epub 2008 Jan 12.
PMID 18192690
 
Take your "M" time.
Baldassarre G, Croce CM, Vecchione A.
Cell Cycle. 2007 Sep 1;6(17):2087-90. Epub 2007 Jun 21.
PMID 17873519
 
Toward a confocal subcellular atlas of the human proteome.
Barbe L, Lundberg E, Oksvold P, Stenius A, Lewin E, Bjorling E, Asplund A, Ponten F, Brismar H, Uhlen M, Andersson-Svahn H.
Mol Cell Proteomics. 2008 Mar;7(3):499-508. Epub 2007 Nov 19.
PMID 18029348
 
Functional identification of LZTS1 as a candidate prostate tumor suppressor gene on human chromosome 8p22.
Cabeza-Arvelaiz Y, Sepulveda JL, Lebovitz RM, Thompson TC, Chinault AC.
Oncogene. 2001 Jul 12;20(31):4169-79.
PMID 11464283
 
FEZ1/LZTS1 protein expression in ovarian cancer.
Califano D, Pignata S, Pisano C, Greggi S, Laurelli G, Losito NS, Ottaiano A, Gallipoli A, Pasquinelli R, De Simone V, Cirombella R, Fusco A, Chiappetta G.
J Cell Physiol. 2010 Feb;222(2):382-6.
PMID 19885841
 
Down-regulation of tumor suppressor gene FEZ1/LZTS1 in breast carcinoma involves promoter methylation and associates with metastasis.
Chen L, Zhu Z, Sun X, Dong XY, Wei J, Gu F, Sun YL, Zhou J, Dong JT, Fu L.
Breast Cancer Res Treat. 2009 Aug;116(3):471-8. Epub 2008 Aug 7.
PMID 18686028
 
Germline sequence variants of the LZTS1 gene are associated with prostate cancer risk.
Hawkins GA, Mychaleckyj JC, Zheng SL, Faith DA, Kelly B, Isaacs SD, Wiley KE, Chang BL, Ewing CM, Bujnovszky P, Bleecker ER, Walsh PC, Meyers DA, Isaacs WB, Xu J.
Cancer Genet Cytogenet. 2002 Aug;137(1):1-7.
PMID 12377406
 
The FEZ1 gene at chromosome 8p22 encodes a leucine-zipper protein, and its expression is altered in multiple human tumors.
Ishii H, Baffa R, Numata SI, Murakumo Y, Rattan S, Inoue H, Mori M, Fidanza V, Alder H, Croce CM.
Proc Natl Acad Sci U S A. 1999 Mar 30;96(7):3928-33.
PMID 10097140
 
FEZ1/LZTS1 gene at 8p22 suppresses cancer cell growth and regulates mitosis.
Ishii H, Vecchione A, Murakumo Y, Baldassarre G, Numata S, Trapasso F, Alder H, Baffa R, Croce CM.
Proc Natl Acad Sci U S A. 2001 Aug 28;98(18):10374-9. Epub 2001 Aug 14.
PMID 11504921
 
Mutation analysis of the 8p candidate tumour suppressor genes DBC2 (RHOBTB2) and LZTS1 in bladder cancer.
Knowles MA, Aveyard JS, Taylor CF, Harnden P, Bass S.
Cancer Lett. 2005 Jul 8;225(1):121-30. Epub 2004 Dec 10.
PMID 15922864
 
DNA copy numbers profiles in affinity-purified ovarian clear cell carcinoma.
Kuo KT, Mao TL, Chen X, Feng Y, Nakayama K, Wang Y, Glas R, Ma MJ, Kurman RJ, Shih IeM, Wang TL.
Clin Cancer Res. 2010 Apr 1;16(7):1997-2008. Epub 2010 Mar 16.
PMID 20233889
 
Reduced FEZ1/LZTS1 expression and outcome prediction in lung cancer.
Nonaka D, Fabbri A, Roz L, Mariani L, Vecchione A, Moore GW, Tavecchio L, Croce CM, Sozzi G.
Cancer Res. 2005 Feb 15;65(4):1207-12.
PMID 15735004
 
A metastasis modifier locus on human chromosome 8p in uveal melanoma identified by integrative genomic analysis.
Onken MD, Worley LA, Harbour JW.
Clin Cancer Res. 2008 Jun 15;14(12):3737-45.
PMID 18559591
 
Down-regulation of FEZ1/LZTS1 gene with frequent loss of heterozygosity in oral squamous cell carcinomas.
Ono K, Uzawa K, Nakatsuru M, Shiiba M, Mochida Y, Tada A, Bukawa H, Miyakawa A, Yokoe H, Tanzawa H.
Int J Oncol. 2003 Aug;23(2):297-302.
PMID 12851677
 
Differential expression of FEZ1/LZTS1 gene in lung cancers and their cell cultures.
Toyooka S, Fukuyama Y, Wistuba II, Tockman MS, Minna JD, Gazdar AF.
Clin Cancer Res. 2002 Jul;8(7):2292-7.
PMID 12114433
 
Fez1/Lzts1 a new mitotic regulator implicated in cancer development.
Vecchione A, Croce CM, Baldassarre G.
Cell Div. 2007b Aug 24;2:24.
PMID 17718912
 
Down-regulation of leucine zipper putative tumor suppressor 1 is associated with poor prognosis, increased cell motility and invasion, and epithelial-to-mesenchymal transition characteristics in human breast carcinoma.
Wang XX, Zhu Z, Su D, Lei T, Wu X, Fan Y, Li X, Zhao J, Fu L, Dong JT, Fu L.
Hum Pathol. 2011 Oct;42(10):1410-9. Epub 2011 Mar 21.
PMID 21419475
 

Citation

This paper should be referenced as such :
Vecchione, A ; Lavra, L ; Croce, CM
LZTS1 (leucine zipper, putative tumor suppressor 1)
Atlas Genet Cytogenet Oncol Haematol. 2012;16(12):894-897.
Free journal version : [ pdf ]   [ DOI ]
On line version : http://AtlasGeneticsOncology.org/Genes/LZTS1ID367ch8p21.html


Other Solid tumors implicated (Data extracted from papers in the Atlas) [ 3 ]
  Bladder: Urothelial carcinomas
Head and Neck: Oral squamous cell carcinoma
Squamous cell cancer


External links

Nomenclature
HGNC (Hugo)LZTS1   13861
Cards
AtlasLZTS1ID367ch8p21
Entrez_Gene (NCBI)LZTS1  11178  leucine zipper, putative tumor suppressor 1
AliasesF37; FEZ1
GeneCards (Weizmann)LZTS1
Ensembl hg19 (Hinxton)ENSG00000061337 [Gene_View]  chr8:20103676-20112803 [Contig_View]  LZTS1 [Vega]
Ensembl hg38 (Hinxton)ENSG00000061337 [Gene_View]  chr8:20103676-20112803 [Contig_View]  LZTS1 [Vega]
ICGC DataPortalENSG00000061337
TCGA cBioPortalLZTS1
AceView (NCBI)LZTS1
Genatlas (Paris)LZTS1
WikiGenes11178
SOURCE (Princeton)LZTS1
Genetics Home Reference (NIH)LZTS1
Genomic and cartography
GoldenPath hg19 (UCSC)LZTS1  -     chr8:20103676-20112803 -  8p22   [Description]    (hg19-Feb_2009)
GoldenPath hg38 (UCSC)LZTS1  -     8p22   [Description]    (hg38-Dec_2013)
EnsemblLZTS1 - 8p22 [CytoView hg19]  LZTS1 - 8p22 [CytoView hg38]
Mapping of homologs : NCBILZTS1 [Mapview hg19]  LZTS1 [Mapview hg38]
OMIM133239   606551   
Gene and transcription
Genbank (Entrez)AF123652 AF123654 AF123655 AF123656 AF123657
RefSeq transcript (Entrez)NM_021020
RefSeq genomic (Entrez)NC_000008 NC_018919 NG_015834 NT_167187 NW_004929337
Consensus coding sequences : CCDS (NCBI)LZTS1
Cluster EST : UnigeneHs.521432 [ NCBI ]
CGAP (NCI)Hs.521432
Alternative Splicing GalleryENSG00000061337
Gene ExpressionLZTS1 [ NCBI-GEO ]   LZTS1 [ EBI - ARRAY_EXPRESS ]   LZTS1 [ SEEK ]   LZTS1 [ MEM ]
Gene Expression Viewer (FireBrowse)LZTS1 [ Firebrowse - Broad ]
SOURCE (Princeton)Expression in : [Datasets]   [Normal Tissue Atlas]  [carcinoma Classsification]  [NCI60]
GenevisibleExpression in : [tissues]  [cell-lines]  [cancer]  [perturbations]  
BioGPS (Tissue expression)11178
GTEX Portal (Tissue expression)LZTS1
Protein : pattern, domain, 3D structure
UniProt/SwissProtQ9Y250   [function]  [subcellular_location]  [family_and_domains]  [pathology_and_biotech]  [ptm_processing]  [expression]  [interaction]
NextProtQ9Y250  [Sequence]  [Exons]  [Medical]  [Publications]
With graphics : InterProQ9Y250
Splice isoforms : SwissVarQ9Y250
PhosPhoSitePlusQ9Y250
Domain families : Pfam (Sanger)
Domain families : Pfam (NCBI)
Conserved Domain (NCBI)LZTS1
DMDM Disease mutations11178
Blocks (Seattle)LZTS1
SuperfamilyQ9Y250
Human Protein AtlasENSG00000061337
Peptide AtlasQ9Y250
HPRD05945
IPIIPI00026058   IPI00410061   IPI00410062   IPI00410063   IPI00410064   IPI00410065   IPI00410066   
Protein Interaction databases
DIP (DOE-UCLA)Q9Y250
IntAct (EBI)Q9Y250
FunCoupENSG00000061337
BioGRIDLZTS1
STRING (EMBL)LZTS1
ZODIACLZTS1
Ontologies - Pathways
QuickGOQ9Y250
Ontology : AmiGODNA binding  transcription factor activity, sequence-specific DNA binding  protein binding  cytoplasm  transcription, DNA-templated  regulation of transcription, DNA-templated  cell cycle  postsynaptic density  negative regulation of macroautophagy  apical plasma membrane  cell junction  dendritic spine  dendritic shaft  cell body  postsynaptic membrane  regulation of synaptic plasticity  regulation of dendrite morphogenesis  
Ontology : EGO-EBIDNA binding  transcription factor activity, sequence-specific DNA binding  protein binding  cytoplasm  transcription, DNA-templated  regulation of transcription, DNA-templated  cell cycle  postsynaptic density  negative regulation of macroautophagy  apical plasma membrane  cell junction  dendritic spine  dendritic shaft  cell body  postsynaptic membrane  regulation of synaptic plasticity  regulation of dendrite morphogenesis  
NDEx NetworkLZTS1
Atlas of Cancer Signalling NetworkLZTS1
Wikipedia pathwaysLZTS1
Orthology - Evolution
OrthoDB11178
GeneTree (enSembl)ENSG00000061337
Phylogenetic Trees/Animal Genes : TreeFamLZTS1
HOVERGENQ9Y250
HOGENOMQ9Y250
Homologs : HomoloGeneLZTS1
Homology/Alignments : Family Browser (UCSC)LZTS1
Gene fusions - Rearrangements
Polymorphisms : SNP and Copy number variants
NCBI Variation ViewerLZTS1 [hg38]
dbSNP Single Nucleotide Polymorphism (NCBI)LZTS1
dbVarLZTS1
ClinVarLZTS1
1000_GenomesLZTS1 
Exome Variant ServerLZTS1
ExAC (Exome Aggregation Consortium)LZTS1 (select the gene name)
Genetic variants : HAPMAP11178
Genomic Variants (DGV)LZTS1 [DGVbeta]
DECIPHER (Syndromes)8:20103676-20112803  ENSG00000061337
CONAN: Copy Number AnalysisLZTS1 
Mutations
ICGC Data PortalLZTS1 
TCGA Data PortalLZTS1 
Broad Tumor PortalLZTS1
OASIS PortalLZTS1 [ Somatic mutations - Copy number]
Somatic Mutations in Cancer : COSMICLZTS1  [overview]  [genome browser]  [tissue]  [distribution]  
Mutations and Diseases : HGMDLZTS1
LOVD (Leiden Open Variation Database)Whole genome datasets
LOVD (Leiden Open Variation Database)LOVD - Leiden Open Variation Database
LOVD (Leiden Open Variation Database)LOVD 3.0 shared installation
BioMutasearch LZTS1
DgiDB (Drug Gene Interaction Database)LZTS1
DoCM (Curated mutations)LZTS1 (select the gene name)
CIViC (Clinical Interpretations of Variants in Cancer)LZTS1 (select a term)
intoGenLZTS1
NCG5 (London)LZTS1
Cancer3DLZTS1(select the gene name)
Impact of mutations[PolyPhen2] [SIFT Human Coding SNP] [Buck Institute : MutDB] [Mutation Assessor] [Mutanalyser]
Diseases
OMIM133239    606551   
Orphanet
MedgenLZTS1
Genetic Testing Registry LZTS1
NextProtQ9Y250 [Medical]
TSGene11178
GENETestsLZTS1
Huge Navigator LZTS1 [HugePedia]
snp3D : Map Gene to Disease11178
BioCentury BCIQLZTS1
ClinGenLZTS1
Clinical trials, drugs, therapy
Chemical/Protein Interactions : CTD11178
Chemical/Pharm GKB GenePA30507
Clinical trialLZTS1
Miscellaneous
canSAR (ICR)LZTS1 (select the gene name)
Probes
Litterature
PubMed28 Pubmed reference(s) in Entrez
GeneRIFsGene References Into Functions (Entrez)
CoreMineLZTS1
EVEXLZTS1
GoPubMedLZTS1
iHOPLZTS1
REVIEW articlesautomatic search in PubMed
Last year publicationsautomatic search in PubMed

Search in all EBI   NCBI

© Atlas of Genetics and Cytogenetics in Oncology and Haematology
indexed on : Tue Mar 14 13:43:49 CET 2017

Home   Genes   Leukemias   Solid Tumours   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

For comments and suggestions or contributions, please contact us

jlhuret@AtlasGeneticsOncology.org.